MEdPACTO

Invited to the 'Maryland VIP Business Reception' hosted by the government of Maryland representing Korea

 

Seong-jin Kim, CEO of Medpacto, meets with Maryland Governor Larry Hogan as a representative of Korean biotechnology company leader. Maryland Governor Larry Hogan who is known as “Korean son-in-law” is one of the strong Republican’s next presidential candidates in 2024.

 

SeongJin Kim, CEO of MedPacto, will introduce its U.S. subsidiary that he founded last year at the 'VIP Business Reception in Maryland' that will be held at JW Marriott in Sinbanpo, Seoul on September 16th.

 

SeongJin Kim was invited to take part because of the connection of his business to Maryland. CEO Kim had researched TGF-β at the National Institutes of Health, Maryland, which led him to establish the US corporate in Maryland. While expanding its bio-cluster in a bid to promote  Korean companies’ business to Maryland,  SeongJin Kim has been invited to the reception as a successful Korean Biotechnology company leader with a growth history integral to the conducive environment in Maryland.

 

At the reception, CEO Kim will introduce his US subsidiary MedPacto Therapeutics while presenting Maryland as an integral part of MedPacto’s growth and its bio innovation ecosystem. 

 

Hosted by the government of Maryland while Hogan's visit to Korea, the event will include on-site networking for domestic companies wishing to extend their business to the U.S. Market. 

 

Hogan has been meeting with Korean politicians and enterpreneurs accompanying Mrs. Yumi Hogan during his 9-day schedule starting from the 13th.

 

Maryland is home to some of the biggest names in life sciences, along with up-and-coming industry innovators and the sector’s influentialfederal institutions such as the National Institute of Health (NIH), the Food and Drug Administration(FDA), Johns Hopkins Hospital, and Maryland State University, making it one of the leading bio-clusters stateside. The number of domestic biotechnology companies extending their business to Maryland is also increasing.

 

MedPacto established its U.S. subsidiary, Medpacto Therapeutics,  last year to accelerate global clinical trials and serve as a bridgehead for licensing in/out with potential partnering companies. MedPacto hired  Timothy Allen, an Executive Vice President with more than 20 years of clinical experience at top-tier global pharmaceutical companies, and a clinical expert from the FDA to speed up the global clinical trial. 

 

"Maryland is the very place where CEO Kim had studied TGF-β, progressively moving forward by establishing the U.S. corporate heaadquarters. As a Korean representative biotechnology company that had successfully established its way to Maryland, MedPacto is drawing more and more attention. And the region's highly educated workforce, life sciences talent, as well as large biopharmas make Maryland particularly attractive." stated a MedPacto representative. 

 

Governor Hogan has continued to show signs he may be exploring a presidential run. Hogan has been weighing a presidential bid after he leaves office in January shunning the Republican leadership's invitation to run for a federal senator in the midterm elections in November.

 

Hogan is a moderate member of the Republican Party, he has been serving as the 62nd governor of Maryland since 2015. Governor Hogan has progressively offered a successful growth opportunity to the early stage development and large biopharmaceuticals.

 

A popular Republican in a blue state, Hogan has been a critic of former President Donald Trump and has positioned himself as a 'moderate alternative while continuing his ‘anti-Trump line’, he has further expanded his political career.